E U R O P E A N U R O L O G Y 6 1 ( 2 0 1 2 ) e 1 5

ava i lable at www.sciencedirect .com

journal homepage: www.europeanurology.com

Letter to the Editor

Reply to Apul Goel and Sagorika Paul’s Letter to the

Editor re: Tim O’Brien, Eleanor Ray, Rajinder Singh, Bola

Coker, Ralph Beard, British Association of Urological

Surgeons Section of Oncology. Prevention of Bladder

Tumours after Nephroureterectomy for Primary Upper

Urinary Tract Urothelial Carcinoma: A Prospective,

Multicentre, Randomised Clinical Trial of a Single Post-

operative Intravesical Dose of Mitomycin C (the ODMIT-

C Trial). Eur Urol 2011;60:703–10

The authors’ suggestion of preoperative intravesical mito-

mycin C (MMC) is interesting but purely speculative. There

is not a shred of evidence to support its use in this way. Let’s

get single-dose postoperative MMC embedded into routine

DOIs of original articles: 10.1016/j.eururo.2011.05.064, 10.1016/j.eururo.201

0302-2838/$ – see back matter # 2011 Published by Elsevier B.V. on behalf

urologic practice first, as it is supported by the level 1

evidence of the ODMIT-C trial, and then start exploring

novel approaches.

Conflicts of interest: The author has nothing to disclose.

Tim O’Brien*

Urology Centre, Guys Hospital, London, SE1 9RT, United Kingdom

*Tel. +44 20 71887338; Fax: +44 20 71886787

E-mail address: tim.obrien@gstt.nhs.uk

November 21, 2011

Published online on December 2, 2011

1.11.037

of European Association of Urology. doi:10.1016/j.eururo.2011.11.036